Molecular Staging of Surgical Margins in Oral Squamous Cell Carcinoma Using Promoter Methylation of p16INK4A, Cytoglobin, E-cadherin, and TMEFF2 |
| |
Authors: | Richard J. Shaw MD Andrew J. Hobkirk MBChB BDS George Nikolaidis PhD Julia A. Woolgar PhD Asterios Triantafyllou PhD James S. Brown MD Triantafillos Liloglou PhD Janet M. Risk PhD |
| |
Affiliation: | 1. Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK 2. Regional Maxillofacial Unit, Aintree University Hospitals NHS Trust, Liverpool, UK 3. Cellular Pathology, Aintree University Hospitals NHS Foundation Trust, Liverpool, UK 4. School of Dentistry, University of Liverpool, Liverpool, UK
|
| |
Abstract: |
Background Local recurrence in oral squamous cell carcinoma (OSCC) despite clear surgical margins may indicate the presence of residual, sub-microscopic disease. Molecular assessment of surgical margins may provide a greater prognostic sensitivity compared to histopathology. We aimed to determine whether promoter methylation in deep and mucosal resection margins can predict recurrence in OSCC. Methods Forty-eight consecutive OSCC cases were recruited and a 5 mm3 tumor sample plus 5 deep and 5 mucosal margin samples were snap frozen. Clinical, pathological, adjuvant therapy, and outcome data were recorded. Tumors were informative if >5 % promoter methylation was found for ≥1 of 4 genes using qMSP. Margins were declared molecularly positive if >1 % promoter methylation was found in any margin. Results Thirty (63 %) of 48 cases were methylation informative. Mucosal margin samples were largely positive for methylation (26 of 30, 87 %), indicating the presence of field cancerization. Methylation at ≥1 gene promoters in ≥1 deep margin correlated with the presence of close/involved mucosal margins (P = 0.027) and increased pT status (P = 0.027) but not the status of deep margins, recurrence, or survival. Conclusions The current gene panel did not add prognostic information to histopathological reporting of resection margins. Future efforts should concentrate on improving gene selection, informativity, and assay performance in the patient group with intermediate indications for adjuvant therapy. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|